TrialLeukemia2016
TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy.
E Nievergall et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
35 papers cite it
this paperpooled ittrialcites it